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Abstract
The purpose of the present study was to identify genetic variants that confer susceptibility to dyslipidemia. A total of 5213 individuals from
two independent populations were examined: Subject panel A comprised 3794 individuals who visited participating hospitals; subject panel B
comprised 1419 community-dwelling elderly individuals. The genotypes for 100 polymorphisms of 65 candidate genes were determined. The χ2
test and multivariable logistic regression analysis revealed that seven polymorphisms of APOA5, APOC3, APOA1, ACAT2, and LPL were
significantly associated with hypertriglyceridemia, six polymorphisms of APOA5, LIPC, and CYP3A4 with low HDL-cholesterol, and three
polymorphisms of APOE and CCR2 with high LDL-cholesterol in subject panel A. For validation of these associations, the same polymorphisms
were examined in subject panel B. Six polymorphisms of APOA5, APOC3, APOA1, and LPL were again significantly associated with
hypertriglyceridemia, three polymorphisms of APOA5 with low HDL-cholesterol, and two polymorphisms of APOE with high LDL-cholesterol.
Serum triglyceride, HDL-cholesterol, and LDL-cholesterol concentrations differed significantly among genotypes of these corresponding
polymorphisms in both subject panels. These results indicate that polymorphisms of APOA5, APOC3, APOA1, and LPL are determinants of
hypertriglyceridemia and that those of APOA5 and APOE are determinants of low HDL-cholesterol and high LDL-cholesterol, respectively, in
Japanese individuals.
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interaction between genetic and environmental factors, the latter
including a high-fat and high-calorie diet and physical inactivity
[1]. Although genetic linkage analyses [2–4] and candidate
gene approaches [5–8] have implicated several loci and
candidate genes for predisposition to dyslipidemia, the genes
that confer susceptibility to this condition remain to be
identified definitively. In addition, given ethnic differences in⁎ Corresponding author. Fax: +81 59 231 5388.
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doi:10.1016/j.ygeno.2007.08.001lifestyle and environmental factors as well as in genetic
background, it is important to examine gene polymorphisms
related to dyslipidemia in each ethnic group.
We have now performed a large-scale association study for
100 polymorphisms of 65 candidate genes and dyslipidemia in
5213 Japanese individuals. Given that dyslipidemia includes
hypertriglyceridemia, a low serum concentration of high-
density lipoprotein (HDL) cholesterol, and a high serum
concentration of low-density lipoprotein (LDL) cholesterol,
each of which is an important risk factor for atherosclerosis, we
examined the relations of genetic variants to each of these
552 Y. Yamada et al. / Genomics 90 (2007) 551–558conditions separately. The purpose of the present study was thus
to identify gene polymorphisms associated with dyslipidemia
and thereby to contribute to the prediction of the genetic risk for
this condition.
Results
The characteristics of subject panels A and B are shown in
Table 1. Evaluation of genotype distributions by the χ2 test
revealed that seven polymorphisms were significantly (false
discovery rate (FDR) b0.05) associated with hypertriglycer-
idemia, six with low HDL-cholesterol, and three with high
LDL-cholesterol in subject panel A (Supplementary Table 1).
The identified polymorphisms were examined further by
multivariable logistic regression analysis with adjustment for
age, sex, and the prevalence of diabetes mellitus. The
−1131T→C, −3A→G, and 553G→T (Gly185Cys) poly-
morphisms of APOA5 (all genetic models), the 1100C→T
polymorphism of APOC3 (all models), the 84T→C poly-
morphism of APOA1 (dominant and additive 1 and 2 models),
the 41A→G (Glu14Gly) polymorphism of ACAT2 (all
models), and the 1595C→G (Ser447Stop) polymorphism of
LPL (dominant and additive 1 models) were significantly
(pb0.05) associated with hypertriglyceridemia in subject panel
A (Supplementary Table 2). The −1131T→C, 553G→T
(Gly185Cys), and −3A→G polymorphisms of APOA5 (all
models), the −250G→A and −514C→T polymorphisms of
LIPC (all models), and the 13989A→G (Ile118Val) poly-
morphism of CYP3A4 (dominant and additive 1 models) were
significantly associated with low HDL-cholesterol in subject
panel A (Supplementary Table 2). The 4070C→T (Arg158Cys)
(dominant and additive 1 models) and 3932T→C (Cys112Arg)Table 1
Characteristics of the 5213 study subjects
Characteristic Subject panel A Subject panel B
No. of subjects 3794 1419
Age (years) 64.8±10.9 72.3±5.6
Sex (male/female, %) 58.5/41.5 47.8/52.2
Body mass index (kg/m2) 23.6±3.3 23.2±3.0
Current or former smoker (%) 18.4 30.4
Hypertension (%) 64.6 37.1
Diabetes mellitus (%) 35.2 7.0
Serum total cholesterol (mmol/L) 5.25±1.01 5.12±0.86
Serum triglycerides (mmol/L) 1.62±1.39 1.58±9.35
Hypertriglyceridemia (%) 35.1 35.9
Serum HDL-cholesterol (mmol/L) 1.35±0.47 1.51±0.39
Low HDL-cholesterol (%) 20.5 8.2
Serum LDL-cholesterol (mmol/L) 3.15±0.91 2.86±0.73
High LDL-cholesterol (%) 26.3 15.2
Data for age, body mass index, and serum lipid concentrations are means±SD.
Smoker, smoking ≥10 cigarettes daily; hypertension, systolic blood pressure of
≥140 mm Hg or diastolic blood pressure of ≥90 mm Hg (or both) or taking
antihypertensive medication; diabetes mellitus, fasting blood glucose of
≥6.93 mmol/L (126 mg/dl) or glycosylated hemoglobin of ≥6.5% (or both)
or taking anti-diabetes medication; hypertriglyceridemia, serum concentration of
triglycerides of ≥1.65 mmol/L (150 mg/dl); low HDL-cholesterol, serum
concentration of HDL-cholesterol of b1.04 mmol/L (40 mg/dl); high LDL-
cholesterol, serum concentration of LDL-cholesterol of ≥3.64 mmol/L
(140 mg/dl).(dominant and additive 1 and 2 models) polymorphisms of
APOE and the 190G→A (Val64Ile) polymorphism of CCR2
(dominant and additive 1 models) were significantly associated
with high LDL-cholesterol in subject panel A (Supplementary
Table 2).
To validate these associations, we examined in subject panel
B the polymorphisms associated with dyslipidemia in subject
panel A. Multivariable logistic regression analysis with
adjustment for age, sex, and the prevalence of diabetes mellitus
revealed that the −1131T→C (all models), −3A→G (all
models), and 553G→T (Gly185Cys) (dominant and additive 1
models) polymorphisms of APOA5, the 1100C→T polymorph-
ism of APOC3 (all models), the 84T→C polymorphism of
APOA1 (all models), and the 1595C→G (Ser447Stop)
polymorphism of LPL (dominant and additive 1 models), but
not the 41A→G (Glu14Gly) polymorphism of ACAT2, were
significantly (pb0.05) associated with hypertriglyceridemia in
subject panel B (Supplementary Table 3). The −1131T→C (all
models), 553G→T (Gly185Cys) (dominant and additive 1
models), and −3A→G (all models) polymorphisms of APOA5,
but not the −250G→A or −514C→T polymorphisms of LIPC
or the 13989A→G (Ile118Val) polymorphism of CYP3A4,
were significantly associated with low HDL-cholesterol in
subject panel B (Supplementary Table 3). The 4070C→T
(Arg158Cys) and 3932T→C (Cys112Arg) polymorphisms of
APOE (dominant and additive 1 models), but not the
190G→A (Val64Ile) polymorphism of CCR2, were signifi-
cantly associated with high LDL-cholesterol in subject panel B
(Supplementary Table 3).
Genotype distributions in subject panels A or B of the
polymorphisms identified by the χ2 test are shown in
Supplementary Table 4. The genotype distributions of these
13 polymorphisms in individuals of subject panels A and B
were all in Hardy–Weinberg equilibrium.
We next examined the relations of serum concentrations of
triglycerides, HDL-cholesterol, or LDL-cholesterol to geno-
types of each polymorphism. Serum triglyceride concentration
differed significantly among genotypes for the −1131T→C,
−3A→G, and 553G→T (Gly185Cys) polymorphisms of
APOA5, the 1100C→T polymorphism of APOC3, the
84T→C polymorphism of APOA1, and the 1595C→G
(Ser447Stop) polymorphism of LPL in both subject panels A
and B (Table 2). Serum HDL-cholesterol concentration differed
significantly among genotypes for the −1131T→C, 553G→T
(Gly185Cys), and −3A→G polymorphisms of APOA5 as well
as the −250G→A and −514C→T polymorphisms of LIPC in
both subject panels A and B (Table 2). Serum LDL-cholesterol
concentration differed significantly among genotypes for the
4070C→T (Arg158Cys) and 3932T→C (Cys112Arg) poly-
morphisms of APOE in both subject panels A and B (Table 2).
Finally, we examined linkage disequilibrium among poly-
morphisms of APOA5, APOA1, and APOC3 (located at
chromosome 11q23) and of APOE, as well as the relations of
haplotypes of these polymorphisms to hypertriglyceridemia, low
HDL-cholesterol, and high LDL-cholesterol. The −1131T→C,
−3A→G, and 553G→T (Gly185Cys) polymorphisms of
APOA5, the 84T→C polymorphism of APOA1, and the
Table 2
Serum concentrations of triglycerides, HDL-cholesterol, and LDL-cholesterol according to genotypes in subject panels A and B
Gene
symbol
Polymorphism Subject panel A Subject panel B
11 12 22 P 11 12 22 P
Serum concentration of triglycerides (mmol/L)
APOA5 −1131T→C 1.39±0.84
(1640)
1.72±1.45
(1687)
2.02±2.24
(459)
4.8×10−28 1.36±0.73
(617)
1.67±0.97
(627)
2.04±1.21
(175)
4.3×10−17
APOA5 −3A→G 1.39±0.84
(1636)
1.73±1.46
(1686)
2.00±2.24
(459)
1.4×10−25 1.36±0.73
(616)
1.67±0.97
(627)
2.04±1.21
(176)
2.7×10−17
APOA5 553G→T
(Gly185Cys)
1.55±1.20
(3263)
1.89±1.42
(488)
3.75±6.85
(30)
8.0×10−15 1.53±0.89
(1200)
1.87±1.12
(210)
2.18±0.99
(8)
9.5×10−7
APOC3 1100C→T 1.41±0.89
(632)
1.62±1.42
(1811)
1.72±1.51
(1344)
2.8×10−7 1.34±0.75
(252)
1.57±0.91
(677)
1.72±1.02
(490)
4.0×10−7
APOA1 84T→C 1.67±1.40
(2384)
1.53±1.42
(1224)
1.43±0.76
(178)
0.0002 1.64±0.97
(847)
1.52±0.91
(493)
1.33±0.62
(79)
0.0011
ACAT2 41A→G
(Glu14Gly)
1.67±1.58
(2306)
1.64±1.01
(1301)
1.40±0.77
(174)
0.0050 1.56±0.91
(891)
1.64±0.99
(483)
1.40±0.58
(45)
0.4740
LPL 1595C→G
(Ser447Stop)
1.64±1.43
(2917)
1.51±1.12
(815)
1.43±1.60
(55)
5.8×10−6 1.63±0.95
(1090)
1.43±0.86
(309)
1.41±0.80
(20)
0.0007
Serum concentration of HDL-cholesterol (mmol/L)
APOA5 −1131T→C 1.40±0.42
(1652)
1.33±0.49
(1683)
1.27±0.39
(458)
8.6×10−15 1.56±0.39
(617)
1.46±0.36
(627)
1.40±0.39
(175)
5.8×10−9
APOA5 553G→T
(Gly185Cys)
1.38±0.47
(3272)
1.27±0.39
(487)
1.07±0.34
(29)
1.8×10−10 1.53±0.39
(1200)
1.40±0.34
(210)
1.46±0.49
(8)
7.4×10−5
APOA5 −3A→G 1.40±0.42
(1648)
1.35±0.49
(1682)
1.30±0.39
(458)
5.4×10−12 1.56±0.39
(616)
1.46±0.36
(627)
1.40±0.39
(176)
5.9×10−9
LIPC −250G→A 1.30±0.39
(945)
1.35±0.49
(1844)
1.43±0.47
(1005)
2.9×10−11 1.43±0.34
(316)
1.51±0.36
(733)
1.59±0.42
(370)
4.2×10−7
LIPC −514C→T 1.33±0.39
(933)
1.35±0.49
(1897)
1.43±0.47
(958)
2.6×10−9 1.43±0.34
(325)
1.51±0.39
(733)
1.59±0.42
(361)
3.8×10−7
CYP3A4 13989A→G
(Ile118Val)
1.35±0.47
(3747)
1.51±0.26
(40)
0.0007 1.51±0.39
(1419)
Serum concentration of LDL-cholesterol (mmol/L)
APOE 4070C→T
(Arg158Cys)
3.17±0.91
(3387)
2.76±0.83
(288)
2.31±1.12
(8)
3.6×10−17 2.91±0.73
(1293)
2.39±0.68
(123)
1.82±0.47
(3)
3.6×10−14
APOE 3932T→C
(Cys112Arg)
3.09±0.91
(2949)
3.28±0.88
(696)
3.56±0.91
(38)
4.2×10−8 2.83±0.73
(1155)
2.99±0.75
(252)
2.81±0.94
(12)
0.0068
CCR2 190G→A
(Val64Ile)
3.09±0.88
(1885)
3.20±0.91
(1487)
3.15±0.94
(311)
0.0013 2.89±0.75
(734)
2.83±0.73
(573)
2.96±0.75
(112)
0.2413
Numbers of subjects are shown in parentheses. 11, wild-type homozygote; 12, heterozygote; 22, variant homozygote.
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disequilibrium (Supplementary Table 5). Haplotype analysis
revealed that the haplotypes T (−1131T→C of APOA5)–A
(−3A→G of APOA5)–G (553G→T of APOA5)–T (84T→C
of APOA1)–T (1100C→T of APOC3), T–A–G–C–C, and T–
A–G–T–C were protective against hypertriglyceridemia,
whereas the haplotypes C–G–G–T–T, C–G–T–T–T, C–G–
G–C–C, and C–A–G–T–T were risk factors for this condition
(Table 3). Similar analysis revealed that the haplotypes T–A–
G–T–T and T–A–G–C–C were protective against low HDL-
cholesterol, whereas the haplotypes C–G–G–T–T, C–G–T–T–
T, C–G–G–T–C, C–A–G–T–T, and T–A–T–T–T were risk
factors for this condition (Table 4). The 4070C→T (Arg158Cys)
and 3932T→C (Cys112Arg) polymorphisms of APOE were in
strong linkage disequilibrium (D′=−0.9866, p=1.2×10−8).
Haplotype analysis revealed that the haplotype C (4070C→T
of APOE)–C (3932T→C of APOE), which results in the pro-duction of the Apo E4 isoform, was a risk factor for high LDL-
cholesterol, whereas the haplotype T–T, which results in the
production of the Apo E2 isoform, was protective against this
condition (Table 5).
Discussion
We have examined the relations of 100 polymorphisms in 65
candidate genes to hypertriglyceridemia, low HDL-cholesterol,
and high LDL-cholesterol in 5213 Japanese individuals from
two independent populations. Our large-scale association study
revealed that the −1131T→C, −3A→G, and 553G→T
(Gly185Cys) polymorphisms of APOA5, the 1100C→T
polymorphism of APOC3, the 84T→C polymorphism of
APOA1, and the 1595C→G (Ser447Stop) polymorphism of
LPL were significantly associated with hypertriglyceridemia;
the −1131T→C, −3A→G, and 553G→T (Gly185Cys)
Table 3
Association of hypertriglyceridemia with APOA5-APOA1-APOC3 haplotypes in combined subject panels A and B
Haplotype Overall
frequency
Frequency χ2 test
p value
Permutation
p value
Hypertriglyceridemia (−) Hypertriglyceridemia (+)
T–A–G–T–T 0.2740 0.2868 0.2508 8.5×10−5 0.001
C–G–G–T–T 0.2437 0.2253 0.2778 2.7×10−9 0
T–A–G–C–C 0.1925 0.2114 0.1572 2.0×10−11 0
T–A–G–T–C 0.1796 0.1879 0.1647 0.0032 0.001
C–G–T–T–T 0.0622 0.0490 0.0863 5.1×10−14 0
C–G–G–T–C 0.0116 0.0100 0.0149 0.0256 0.084
C–G–G–C–C 0.0106 0.0081 0.0147 0.0014 0.012
C–G–T–C–C 0.0059 0.0048 0.0085 0.0225 0.077
C–A–G–T–T 0.0051 0.0030 0.0084 0.0002 0.001
C–G–T–T–C 0.0042 0.0030 0.0061 0.0171 0.088
T–A–G–C–T 0.0031 0.0029 0.0035 0.5648 0.616
T–G–G–T–T 0.0022 0.0024 0.0018 0.5317 0.561
T–G–G–T–C 0.0013 0.0015 0.0011 0.6490 0.739
T–G–G–C–C 0.0010 0.0006 0.0016 0.0961 0.243
T–G–T–T–C 0.0008 0.0008 0.0006 0.8116 0.882
T–G–T–T–T 0.0004 0.0004 0.0004 0.9763 0.982
C–G–G–C–T 0.0004 0.0006 2.1×10−22 0.1233 0.276
C–A–G–T–C 0.0004 1.1×10−7 0.0007 0.0298 0.088
T–A–T–C–C 0.0003 0.0004 5.0×10−8 0.2275 0.540
T–G–T–C–C 0.0002 0.0006 6.7×10−21 0.1474 0.301
T–A–T–T–C 0.0002 0.0002 0.0004 0.5200 0.886
T–A–T–T–T 0.0002 3.9×10−21 0.0004 0.1034 0.190
C–A–G–C–C 0.0001 0.0005 8.2×10−65 0.1567 0.218
C–A–G–C–T 0.0001 9.2×10−34 0.0002 0.2943 0.352
Haplotypes consist of the −1131T→C, −3A→G, and 553G→T polymorphisms of APOA5, the 84T→C polymorphism of APOA1, and the 1100C→T
polymorphism of APOC3.
554 Y. Yamada et al. / Genomics 90 (2007) 551–558polymorphisms of APOA5 were significantly associated with
low HDL-cholesterol; and the 4070C→T (Arg158Cys) and
3932T→C (Cys112Arg) polymorphisms of APOE were
significantly associated with high LDL-cholesterol.
APOA5, APOA1, and APOC3
The apolipoprotein gene cluster (APOA5–APOA1–APOC3–
APOA4) on chromosome 11q23 is a region of the genome
linked to plasma lipid levels as a quantitative trait. APOA5 is
located ∼27 kb upstream of the well-characterized APOA1–
APOC3–APOA4 gene cluster [9] and was found to be strongly
associated with plasma triglyceride level [10]. Human APOA5
consists of four exons and encodes a 369—amino-acid protein
[10]. Functional studies in mice indicate that altering the level of
APOA5 expression substantially affects plasma triglyceride
level. The plasma triglyceride concentration of transgenic mice
that express human APOA5 was thus found to be one-third that
of control mice, whereas that of APOA5 knockout mice was
four times that of controls [10].
The −1131T→C polymorphism in the promoter region of
human APOA5 was found to be independently associated with
plasma triglyceride level in populations of various ethnicities,
with the variant C allele being a risk factor for increased
triglyceride concentrations [7,10–14]. This polymorphism was
also associated with HDL-cholesterol level in addition to
triglyceride level in both Asian and Caucasian populations, with
individuals with the C allele exhibiting reduced HDL-
cholesterol concentrations [7,12–14]. The −3A→G [7,15]and 553G→T (Gly185Cys) [16] polymorphisms of APOA5,
which are in linkage disequilibrium with the −1131T→C
polymorphism, have also been associated with variation in
triglyceride levels. These observations thus indicate that
APOA5 is important in the regulation of triglyceride and
HDL-cholesterol concentrations in humans. We have now
shown that the −1131T→C, −3A→G, and 553G→T
(Gly185Cys) polymorphisms of APOA5 were associated with
hypertriglyceridemia and low HDL-cholesterol, with the variant
C, G, and T alleles, respectively, representing risk factors for
these conditions. Our data are thus consistent with the results of
previous studies [7,12–16].
The molecular mechanism for the effect of apolipoprotein
A–V on triglyceride metabolism remains unclear. Apolipopro-
tein A–V exhibits a high-affinity, low-elasticity, and slow
binding kinetics at hydrophobic interfaces [17], properties that
may retard the assembly of triglyceride-rich particles. In
addition to the observation that the level of very low density
lipoprotein (VLDL) triglycerides was markedly decreased in
APOA5 transgenic mice [10], in vitro studies have shown that
recombinant apolipoprotein A–V interacts with and increases
the activity of lipoprotein lipase [18]. Apolipoprotein A–V
might thus reduce VLDL-triglyceride levels by both down-
regulating hepatic VLDL synthesis and increasing VLDL
clearance.
Apolipoprotein C-III, a 79-amino-acid glycoprotein, is
synthesized by the liver and small intestine and is a major
component of triglyceride-rich lipoproteins and HDL. This
protein is important in regulation of the serum concentration of
Table 4
Association of low HDL-cholesterol with APOA5–APOA1–APOC3 haplotypes in combined subject panels A and B
Haplotype Overall
frequency
Frequency χ2 test
p value
Permutation
p value
Low HDL-cholesterol (−) Low HDL-cholesterol (+)
T–A–G–T–T 0.2735 0.2823 0.2304 7.1×10−6 0
C–G–G–T–T 0.2433 0.2379 0.2694 0.0048 0.006
T–A–G–C–C 0.1932 0.1985 0.1658 0.0014 0.003
T–A–G–T–C 0.1802 0.1825 0.1708 0.2421 0.268
C–G–T–T–T 0.062 0.0546 0.0975 7.8×10−12 0
C–G–G–T–C 0.0115 0.0102 0.0175 0.0083 0.039
C–G–G–C–C 0.0105 0.0106 0.0100 0.8209 0.877
C–G–T–C–C 0.0056 0.0062 0.0053 0.6674 0.738
C–A–G–T–T 0.0051 0.0039 0.0109 0.0001 0
C–G–T–T–C 0.0043 0.0032 0.0078 0.0049 0.062
T–A–G–C–T 0.0034 0.0028 0.0059 0.0369 0.076
T–G–G–T–T 0.0022 0.0023 0.0018 0.6616 0.698
T–G–G–T–C 0.0013 0.0012 0.0022 0.2781 0.397
T–G–G–C–C 0.0010 0.0008 0.0011 0.7058 0.796
T–G–T–T–C 0.0007 0.0008 4.6×10−11 0.2202 0.482
T–G–T–T–T 0.0004 0.0006 1.4×10−55 0.3145 0.340
C–G–G–C–T 0.0004 0.0005 2.3×10−18 0.3310 0.267
C–A–G–T–C 0.0004 0.0003 0.0009 0.2314 0.149
T–A–T–C–C 0.0003 0.0002 0.0007 0.2757 0.256
T–G–T–C–C 0.0002 0.0002 0.0006 0.4170 0.486
T–A–T–T–C 0.0002 0.0003 5.5×10−19 0.4985 0.270
T–A–T–T–T 0.0001 5.2×10−21 0.0009 0.0063 0.025
C–A–G–C–C 0.0001 0.0001 0.0002 0.4801 0.344
C–A–G–C–T 4.9×10−5 1.1×10−38 0.0004 0.0677 0.199
Haplotypes consist of the −1131T→C, −3A→G, and 553G→T polymorphisms of APOA5, the 84T→C polymorphism of APOA1, and the 1100C→T
polymorphism of APOC3.
555Y. Yamada et al. / Genomics 90 (2007) 551–558triglycerides [19]. It inhibits lipolysis of VLDL, both through
inhibition of lipoprotein lipase and hepatic triglyceride lipase
activity and by interfering with lipoprotein binding to
glycosaminoglycans on cell membranes [20]. Several poly-
morphisms in or near APOC3 have been associated with
hypertriglyceridemia. A polymorphic SstI site (3238C→G) in
the 3′ untranslated region of APOC3 has been associated with
hypertriglyceridemia in various populations [6,9]. The
1100C→T polymorphism of APOC3 was also shown to be
associated with the serum concentration of triglycerides [21].
We have now shown that the 1100C→T polymorphism of
APOC3 was associated with hypertriglyceridemia, with the T
allele being a risk factor for this condition.
Apolipoprotein A–I is synthesized in the liver and, to a
lesser extent, in the small intestine and is the major protein
found in HDL [9]. This protein plays an important role inTable 5
Association of high LDL-cholesterol with APOE haplotypes in combined
subject panels A and B
Haplotype Overall
frequency
Frequency χ2 test
p value
Permutation
p value
High LDL-
cholesterol
(−)
High LDL-
cholesterol
(+)
C–T 0.8553 0.8572 0.8506 0.4261 0.439
C–C 0.1022 0.0946 0.1262 8.5×10−6 0
T–T 0.0420 0.0478 0.0213 1.6×10−8 0
T–C 0.0005 0.0004 0.0019 0.0261 0.256
Haplotypes consist of the 4070C→T and 3932T→C polymorphisms of APOE.cellular cholesterol homeostasis. It serves as a cofactor for the
enzyme lecithin:cholesterol acyltransferase and is therefore a
major player in the regulation of reverse cholesterol transport
from peripheral tissues to the liver [9]. This pathway is
thought to be protective against atherosclerosis. Indeed,
transgenic mice that express human APOA1 have been
shown to be resistant to the development of diet-induced
atherosclerosis [22]. The 84T→C polymorphism of APOA1
was previously associated with the serum concentrations of
triglycerides and HDL-cholesterol [23]. We have now shown
that the 84T→C polymorphism of APOA1 was associated
with hypertriglyceridemia, with the C allele being protective
against this condition.
LPL
Lipoprotein lipase (LPL) is the rate-limiting enzyme in
lipolysis of triglyceride-rich lipoproteins in the circulation. It is
synthesized in parenchymal cells of adipose tissue as well as in
skeletal and cardiac muscle, and it is then transferred to heparan
sulfate binding sites of the vascular endothelium [24]. The
hydrolytic function of LPL is important for the processing of
triglyceride-rich chylomicrons and VLDL to remnant particles
as well as for the transfer of phospholipids and apolipoproteins
to HDL. LPL also plays an important role in the receptor-
mediated removal of lipoproteins from the circulation [25]. LPL
is polymorphic, with amino acid substitutions affecting
triglyceride and HDL-cholesterol levels, both of which are
implicated in atherosclerosis risk [26]. The 1595C→G
556 Y. Yamada et al. / Genomics 90 (2007) 551–558(Ser447Stop) polymorphism of LPL results in carboxyl-
terminal truncation of LPL by two amino acids. This change
is thought to increase the binding affinity of the protein for
receptors or to facilitate or otherwise affect its formation of
dimers [26]. The G allele of the 1595C→G (Ser447Stop)
polymorphism has also been shown to be related to decreased
plasma triglyceride or increased HDL-cholesterol levels, or both
[5,25,26]. Previous observations suggest that the catalytic
activity and stability of the truncated variant of LPL may be
largely normal, but that it may be present at higher concentra-
tions in the circulation, resulting in a higher level of LPL
activity [25,27]. We have now shown that the 1595C→G
(Ser447Stop) polymorphism of LPL was associated with
hypertriglyceridemia, with the G (Stop) allele protecting against
this condition, consistent with the previous observations
[5,25,26].
APOE
Apolipoprotein E plays an important role in lipid transport
and metabolism. Three common alleles (ε2, ε3, and ε4) of
APOE encode the three major isoforms (E2, E3, and E4),
which differ at amino acid positions 112 and 158. Allelic
variation of APOE accounts for interindividual variability in
total cholesterol and LDL-cholesterol concentrations, with
studies in human populations demonstrating associations of the
ε4 and ε2 alleles with increased and decreased LDL-
cholesterol levels, respectively [28–30]. The various apolipo-
protein E isoforms interact differently with specific lipoprotein
receptors, ultimately affecting circulating levels of cholesterol
[31]. Apolipoprotein E from VLDL, chylomicrons, and
chylomicron remnants binds to specific receptor cells in the
liver. Carriers of the ε2 allele are less efficient at synthesizing
VLDL and chylomicrons and at transferring them from plasma
to the liver as a result of the binding properties of the Apo E2
isoform. In contrast, these processes are much more efficient in
carriers of the ε3 or ε4 alleles. Thus, compared with carriers of
the ε3 or ε4 alleles, carriers of the ε2 allele are slower to clear
dietary fat from their blood [32]. The difference in uptake of
postprandial lipoprotein particles results in differences in
regulation of hepatic LDL receptors, which in turn contribute
to genotypic differences in total and LDL-cholesterol levels
[33–35].
In the present study, we observed that the 4070C→T
(Arg158Cys) and 3932T→C (Cys112Arg) polymorphisms of
APOE were associated with high LDL-cholesterol, with the
4070T allele and the haplotype that encodes the E2 isoform
being protective against this condition and with the 3932C allele
and the haplotype that encodes the E4 isoform representing risk
factors for this condition. Our results are thus consistent with
previous observations [8,28–30,33–35].
Conclusion
Our results suggest that APOA5, APOC3, APOA1, and LPL
are determinants of hypertriglyceridemia and that APOA5 and
APOE are determinants of low HDL-cholesterol and highLDL-cholesterol, respectively, in the Japanese population.
Genotyping of these polymorphisms may prove informative
for prediction of the genetic risk for these conditions.
Materials and methods
Study populations
A total of 5213 individuals from two independent populations was
examined. Subject panel A comprised 3794 individuals who either visited
outpatient clinics of or were admitted to the participating hospitals (Gifu
Prefectural General Medical Center, Gifu Prefectural Tajimi Hospital, and Gifu
Prefectural Gero Hot Spring Hospital in Gifu Prefecture, Japan, and Hirosaki
University Hospital, Reimeikyo Rehabilitation Hospital, and Hirosaki Stroke
Center in Aomori Prefecture, Japan) between October 2002 and March 2007
because of various symptoms or for an annual health checkup; subject panel B
comprised 1419 community-dwelling elderly individuals recruited to a
population-based prospective cohort study of aging and age-related diseases
in Gunma Prefecture, Japan.
The study protocol complied with the Declaration of Helsinki and was
approved by the Committees on the Ethics of Human Research of Mie
University School of Medicine, Hirosaki University School of Medicine, Gifu
International Institute of Biotechnology, Tokyo Metropolitan Institute of
Gerontology, and the participating hospitals. Written informed consent was
also obtained from each participant.
Measurement of serum lipid profile
Venous blood was collected in the early morning after the subjects had
fasted overnight and before they had begun lipid-lowering treatment as
appropriate. Blood samples were centrifuged at 1600g for 15 min at 4°C, and
serum was separated and stored at −30°C until analysis. The serum
concentrations of total cholesterol [36], triglycerides [37], and HDL-cholesterol
[38] were measured as described previously. The serum concentration of LDL-
cholesterol was also measured as previously described [39] or was calculated
by the Friedewald formula [serum concentration of LDL-cholesterol=serum
concentration of total cholesterol−serum concentration of HDL-cholesterol
− (0.2×serum concentration of triglycerides)] when the serum triglyceride
concentration was ≤4.4 mmol/L [40,41].
Selection of polymorphisms
Our aim was to identify genes associated with dyslipidemia in the Japanese
population in a case–control association study by examining the relation of one
to five polymorphisms of each candidate gene to this condition. With the use of
public databases, including PubMed (NCBI) and Online Mendelian Inheritance
in Man (NCBI), we selected 65 candidate genes that have been characterized and
suggested to be associated with hypertriglyceridemia or low HDL-cholesterol or
high LDL-cholesterol concentrations. On the basis of published studies and
searches of PubMed, we further selected 100 polymorphisms of these genes—
most located in the promoter region or exons—that might be expected to result
in changes in the function or expression of the encoded protein (Supplementary
Table 6). Wild-type and variant alleles of the polymorphisms were determined
from the original sources.
Genotyping of polymorphisms
Venous blood (7 ml) was collected into tubes containing 50 mmol/L EDTA
(disodium salt), and genomic DNA was isolated with a kit (Genomix; Talent,
Trieste, Italy). Genotypes of the 100 polymorphisms were determined at G&G
Science (Fukushima, Japan) by a method that combines the polymerase chain
reaction and sequence-specific oligonucleotide probes with analysis by
suspension array technology (Luminex 100 flow cytometer; Luminex, Austin,
TX, USA). Primers, probes, and other conditions for genotyping are shown in
Supplementary Table 7. Detailed methodology for genotyping was described
previously [42].
557Y. Yamada et al. / Genomics 90 (2007) 551–558Statistical analysis
Allele frequencies were estimated by the gene counting method, and the χ2
test was used to identify departure from Hardy–Weinberg equilibrium. In the
initial screen, the genotype distribution of each polymorphism was compared
between subjects with hypertriglyceridemia (1=serum triglyceride concentra-
tion ≥1.65 mmol/L, 0=b1.65 mmol/L), low HDL-cholesterol (1=serum
HDL-cholesterol concentration b1.04 mmol/L, 0=≥1.04 mmol/L), or high
LDL-cholesterol (1=serum LDL-cholesterol concentration ≥3.64 mmol/L,
0=b3.64 mmol/L) and individuals without each of these conditions by the χ2
test (2×2) in subject panel A. Given the multiple comparisons of genotypes
with dyslipidemia, we calculated the FDR [43] from the distribution of p
values for the 100 polymorphisms. Polymorphisms with an FDR of b0.05 were
further examined in a more rigorous evaluation of association by multivariable
logistic regression analysis with adjustment for covariates, with hypertriglycer-
idemia, low HDL-cholesterol, or high LDL-cholesterol as a dependent variable
and independent variables including age, sex (0=woman, 1=man), the
prevalence of diabetes mellitus (0=no history of diabetes mellitus, 1=positive
history), and genotype of each polymorphism. Each polymorphism was
assessed according to dominant, recessive, and two additive (additive 1 and 2)
genetic models, and the p value, odds ratio, and 95% confidence interval were
calculated. Each genetic model comprised two groups: the combined group of
variant homozygotes and heterozygotes versus wild-type homozygotes for the
dominant model, variant homozygotes versus the combined group of wild-type
homozygotes and heterozygotes for the recessive model, heterozygotes versus
wild-type homozygotes for the additive 1 model, and variant homozygotes
versus wild-type homozygotes for the additive 2 model. Serum concentrations
of triglycerides, HDL-cholesterol, or LDL-cholesterol were compared among
the three genotype groups for selected polymorphisms by the nonparametric
Kruskal–Wallis test or between two groups by the Wilcoxon rank sum test,
given that these data were not distributed normally (pb0.01 by the
Kolmogorov–Smirnov Lilliefors test). We examined linkage disequilibrium
among polymorphisms of the same gene or locus as well as the associations of
haplotypes with hypertriglyceridemia, low HDL-cholesterol, or high LDL-
cholesterol. For statistical analyses other than the initial screen of polymorph-
isms, a p value of b0.05 was considered significant. Statistical significance was
examined using two-tailed tests performed with JMP version 5.1 software (SAS
Institute, Cary, NC, USA). Linkage disequilibrium and haplotype analyses
were performed with SNPAlyze version 6 software (Dynacom, Yokohama,
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